The Data Supports the Use of Rituxin for ALL

We've been using Rituxin since the beginning of, you know, us ever treating ALL. We started using it because of the MD Anderson data that was a single-center study where they compared their hyper-CVAD regimen with no RituxIn. And so when you look at the historical control, there's about a 30% or so death rate in induction with their older patients versus like 0%. So automatically, you can conclude from this that you have no idea for tuxin impacted outcomes or not. But I would say the thing that improved event-free survival in those studies was you're just better than historical control now.